Q4 2021 Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix FY 2022 guidance on other financial KPIs Barring unforeseen events; growth vs. PY in cc Group | full year guidance vs. PY (cc) Core Net Financial Result Core Tax Rate Expenses expected to be broadly in line vs. 2021 Core tax rate expected to be in the 17-17.5% range: ■ +1% vs. PY mathematical impact of Roche divestment¹ ■ +0-0.5% due to profit mix 1. Roche net income from associated companies was recorded after tax thus lowering the average core tax rate in 2021 and prior years. 46 Investor Relations | Q4 2021 Results 1 NOVARTIS | Reimagining Medicine

View entire presentation